Failing Like A Champ
Every industry needs a mantra. Biotech borrowed “fail fast” from tech and wore it like a badge of progress. It promised courage, iteration, and smarter decisions. But in an environment defined by regulation, patient safety, and timelines that stretch for years, the question isn’t whether we should fail fast. It’s whether we can afford to fail carelessly.
How fast can you fail?
Other Scienz & Lives comics
Full Circle Economy
A sharp biotech satire about habit culture, Big Food, Big Pharma, and the quiet corporate loop that profits when nothing changes. Lives eats chips. Scienz connects the dots. The system does the rest.
Scaling The Unscalable
Recent exits by Novo Nordisk, Takeda, and Galapagos reveal a truth biotech can’t ignore: the science of cell therapy is ahead of the systems built to deliver it. Scaling life itself demands more than investment — it demands reinvention.
Failing Like A Champ
“Fail fast” was meant to drive smarter decisions. Instead, it became a slogan that excuses repetition. In biotech, failure teaches only when it’s deliberate. Everything else is just theater.
From Billions to Bills
Biotech headlines show billion-euro deals, but real success often means surviving another quarter. In this Scienz & Lives story, optimism meets the invoice.
Science Meets Happy Hour
Science fills the program, but networking shapes the outcome. In this Scienz & Lives story, the spotlight shifts from the podium to the people behind the progress.
Funding Nightmares: Science or Vibes?
How many therapies never reach patients because capital flows to the best story instead?
Results Before Rules
What’s the worst that could happen if you skip ethics approval? Let’s say someone’s about to learn what “violation report” means.
Fake it till they fund it
When your fake deck gets more investor interest than your real science, you start to wonder which one the industry actually values.
AI Discovery Engine
In today’s sketch, Scienz unveils their fully AI-driven pipeline. Lives asks the obvious question: what does the AI actually do? And the answer is both impressive and deeply concerning.
Endless Pitch
Decks get edited. Again. And again. Until the science is vague, the font is sacred, and no one remembers what the original idea was. That’s the grind behind fundraising in biotech. You are selling potential, not results. But the pressure to sound like a sure thing...